EZH2 Protects Glioma Stem Cells from Radiation-Induced Cell Death in a MELK/FOXM1-Dependent Manner

Sung-Hak Kim(Neurological Surgery), Kaushal Joshi(Neurological Surgery), Ravesanker Ezhilarasan(The University of Texas MD Anderson Cancer Center), Toshia R. Myers(University of Copenhagen), Jason J. Siu(Neurological Surgery), Chunyu Gu(Neurological Surgery), Mariko Nakano‐Okuno(Neurological Surgery), David Taylor(Neurological Surgery), Mutsuko Minata(Neurological Surgery), Erik P. Sulman(The University of Texas MD Anderson Cancer Center), Jeongwu Lee(Cleveland Clinic Lerner College of Medicine), Krishna Bhat(The University of Texas MD Anderson Cancer Center), Anna Elisabetta Salcini(University of Copenhagen), Ichiro Nakano(Neurological Surgery)
Stem Cell Reports
January 15, 2015
Cited by 175Open Access
Full Text

Abstract

Glioblastoma (GBM)-derived tumorigenic stem-like cells (GSCs) may play a key role in therapy resistance. Previously, we reported that the mitotic kinase MELK binds and phosphorylates the oncogenic transcription factor FOXM1 in GSCs. Here, we demonstrate that the catalytic subunit of Polycomb repressive complex 2, EZH2, is targeted by the MELK-FOXM1 complex, which in turn promotes resistance to radiation in GSCs. Clinically, EZH2 and MELK are coexpressed in GBM and significantly induced in postirradiation recurrent tumors whose expression is inversely correlated with patient prognosis. Through a gain-and loss-of-function study, we show that MELK or FOXM1 contributes to GSC radioresistance by regulation of EZH2. We further demonstrate that the MELK-EZH2 axis is evolutionarily conserved in Caenorhabditis elegans. Collectively, these data suggest that the MELK-FOXM1-EZH2 signaling axis is essential for GSC radioresistance and therefore raise the possibility that MELK-FOXM1-driven EZH2 signaling can serve as a therapeutic target in irradiation-resistant GBM tumors.


Related Papers

No related papers found

Powered by citation graph analysis